MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    What change to expect in duration of benefit per dose when switching from IR CD-LD to IPX203 (ER CD-LD)

    R. Hauser, S. Allard, G. Banisadr, S. Fisher (Tampa, USA)

    Objective: To investigate if duration of benefit (“Good On” time) per dose during immediate-release (IR) carbidopa-levodopa (CD-LD) treatment predicts response to IPX203 conversion. Background: Levodopa’s…
  • 2023 International Congress

    Neurofilament light chain in Huntington’s Disease Like 2: a cross-sectional comparison with Huntington’s Disease.

    DG. Anderson, A. Ferreira-Correia, F. Rodrigues, L. Byrne, EJ. Wild, A. Krause (Glasgow, United Kingdom)

    Objective: The objective of this study was to assess the levels of Neurofilament light chain (NfL) in the blood plasma of patients diagnosed with HDL2…
  • 2023 International Congress

    Regional Atrophy and Motor Speech in PSP

    H. Clark, J. Stierwalt, F. Ali, H. Botha, K. Josephs, J. Whitwell (ROCHESTER, USA)

    Objective: This study examined the association of regional atrophy on MRI and motor speech in PSP. Background: Motor speech impairment is common in PSP[1]. Although…
  • 2023 International Congress

    The association between perceived walking difficulties and gait speed in people with drug naïve/early PD

    SB. Jonasson, M. Lindh-Rengifo, E. Stomrud, O. Hansson, MH. Nilsson (Lund, Sweden)

    Objective: To investigate the association between perceived walking difficulties and gait speed in people with drug naïve or early Parkinson’s disease (PD). Background: Objective aspects…
  • 2023 International Congress

    Frequency of Parkinson disease following COVID-19 infection: a two-year retrospective cohort study

    A. Wang, J. Perez, S. Gunzler (Cleveland, USA)

    Objective: We aimed to utilize a large healthcare research network to determine the risk of developing Parkinson disease following COVID-19 infection compared individuals without COVID-19…
  • 2023 International Congress

    Characterization of at-home sleep macrostructure in Parkinson disease using a wearable sleep monitoring device

    J. Thompson, L. Hirt, D. Kern, A. Baumgartner (AURORA, USA)

    Objective: Determine the viability of a wearable reduced montage EEG device to record sleep in a population of patients with Parkinson disease (PD). Background: Sleep…
  • 2023 International Congress

    Tardive dystonia manifesting in lid-opening apraxia, oromandibular dystonia, and laterocollis after long-term sulpiride use

    S. Brillman, T. Gongalore (Palo Alto, USA)

    Objective: We describe a patient who developed tardive dystonia after sulpiride treatment for over two decades. Few cases have been reported[1-3], thus we offer an…
  • 2023 International Congress

    Correlation between fatigue, sleep dysfunction and health-related quality of life in Parkinson’s disease patients

    EL. Ungureanu, S. Berzunțeanu, ș. Diaconu, A. Zârnoveanu, T. Drăgan, B. Ciocănescu, R. Filip, N. Enache, C. Falup-Pecurariu (Brasov, Romania)

    Objective: To determine the correlation between fatigue, sleep dysfunction and health-related quality of life in Parkinson’s disease (PD) patients. Background: Fatigue and sleep dysfunction are…
  • 2023 International Congress

    miRNAs from blood serum as an early diagnostic biomarker for Parkinson’s disease: A study in an animal model

    MD. Ahmad, PSD. Dholaniya (Hyderabad, India)

    Objective: This work aims to elucidate miRNA-based biomarkers for the early stages of Parkinson`s Disease diagnosis in a chemically induced PD rat model. Background: The…
  • 2023 International Congress

    A 16-week open-label study of the effects of treatment with pimavanserin on activities of daily living in subjects with Parkinson’s disease psychosis (PDP)

    V. Evidente, D. Dekarske, B. Coate, V. Abler (Scottsdale, USA)

    Objective: To examine the effects of pimavanserin on activities of daily living during treatment for Parkinson’s Disease psychosis. Background: Accurate assessment of disability associated with…
  • « Previous Page
  • 1
  • …
  • 360
  • 361
  • 362
  • 363
  • 364
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley